BackLandos Biopharma Overview

Landos Biopharma Current Cash

Landos Biopharma's current cash is $29M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$29.05M
↓ 35.78% YoYΔ $-16.19M vs prior year quarter

Peer average

Loading

Landos Biopharma Current Cash History

Loading

Landos Biopharma vs. peers: Current Cash Comparison

Loading

Landos Biopharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Landos Biopharma (LABP) FAQ

Landos Biopharma (LABP) currently reports a current cash of $29M as of March 2024. That compares with $45M in the prior-year period — down 35.8% year over year. Use the charts on this page to explore Landos Biopharma's current cash history and peer comparisons.

Landos Biopharma's current cash decreased from $45M to $29M — a 35.8% year-over-year decrease (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Landos Biopharma reported $29M in current cash as of March 2024. That compares with $45M in the prior-year period — down 35.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $29M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Landos Biopharma, and consider following LABP for alerts when major investors trade the stock.

Landos Biopharma is classified in the Healthcare sector. On current cash, it currently shows $29M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LABP with unrelated industries.